Log inStart free trialBook a demo
Book a demoLog inStart free trial
Media Database
>
Erik Swain

Erik Swain

Author at healio.com at Healio

Contact this person
Email address
e*****@*******.comGet email address
Influence score
32
Location
United States
Languages
  • English
Covering topics

    View more media outlets and journalists by signing up to Prowly

    View latest data and reach out all from one place
    Sign up for free

    Recent Articles

    healio.com

    Zepbound bests Wegovy in head-to-head weight-loss trial

    Eli Lilly announced top-line results of the SURMOUNT-5 trial in which patients with overweight or obesity assigned tirzepatide lost more weight than those assigned semaglutide. SURMOUNT-5 was a phase 3b clinical trial comparing the GLP-1/GIP receptor agonist tirzepatide (Zepbound, Eli Lilly) with the GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy, Novo Nordisk) for weight loss in patients with
    20 days ago
    healio.com

    Obicetrapib tied to sizable LDL lowering on top of other therapies ...

    CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial. The phase 3 BROOKLYN trial, presented at the American Heart Association Scientific Sessions, included 354 patients diagnosed with heterozygous familial
    about 1 month ago
    healio.com

    Out-of-hospital cardiac arrest survival rates remain below pre-pand...

    CHICAGO — U.S. out-of-hospital cardiac arrest survival rates have improved since the first year of the COVID-19 pandemic, but have not returned to pre-pandemic levels, researchers reported.“The onset of the COVID-19 pandemic marked an abrupt change in health care delivery systems and imposed a substantial stress on frontline providers. Initial studies during the early phases of the
    about 1 month ago
    healio.com

    Nasal spray form of bumetanide may be just as good as oral, IV

    CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported. The results of the phase 1 RSQ-777-02 study of nasal, oral and IV bumetanide in healthy volunteers were presented at the American Heart Association Scientific
    about 1 month ago
    healio.com

    Catheter ablation superior to antiarrhythmic drugs in VT with ische...

    CHICAGO — Catheter ablation improved outcomes compared with antiarrhythmic drug therapy in patients with ventricular tachycardia and ischemic cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.“Patients who have ventricular tachycardia (VT) and shocks have worse outcomes than those who do not,” John L. Sapp, MD, FRCPC, FHRS, FCHRS,
    about 1 month ago
    healio.com

    IV GLP-1 does not reduce death, stroke, organ damage after heart su...

    CHICAGO — Exenatide, an IV GLP-1 receptor agonist, did not improve clinical outcomes compared with placebo in patients undergoing heart surgery, according to the results of the GLORIOUS trial. The researchers also found no differences between a restrictive and a liberal oxygenation strategy in this population.
    about 1 month ago
    healio.com

    In PCI for MI, spironolactone does not meet primary endpoints but m...

    CHICAGO — In patients with acute MI who underwent PCI, spironolactone did not improve the primary composite outcomes but was linked to reduced risk for new or worsening HF, according to new data from the CLEAR SYNERGY (OASIS-9) trial. As Healio previously reported, CLEAR SYNERGY (OASIS-9) was a 2x2 factorial trial in which patients with acute MI who underwent PCI were randomly assigned
    about 1 month ago
    healio.com

    CRISPR gene-editing therapy shows promise as cardiac amyloidosis tr...

    CHICAGO — A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin reduced transthyretin levels in patients with cardiac amyloidosis, researchers reported at the American Heart Association Scientific Sessions.Researchers administered the CRISPR-Cas9-based therapy, nexiguran ziclumeran (nex-z, Intellia/Regeneron) to 36 patients (median age, 78 years; 97% men; 22% Black) with
    about 1 month ago
    healio.com

    Obesity prevalence in US has more than doubled over 30 years, proje...

    The prevalence of obesity in the U.S. more than doubled from 1990 to 2021, and the number of Americans with obesity could reach 260 million by 2050 if trends do not change, researchers reported in The Lancet. “Our analysis lays bare the decades-long failure to tackle the growing overweight and obesity epidemic in the USA. The catastrophic consequences of the surge in overweight and obesity
    about 1 month ago
    healio.com

    Cerebral embolic protection may help prevent stroke after TAVR, but...

    WASHINGTON — In an exploratory analysis of the PROTECTED TAVR trial of patients undergoing transcatheter aortic valve replacement, cerebral embolic protection reduced risk for short-term stroke in patients from the U.S. but not elsewhere. As Healio previously reported, in the main findings of PROTECTED TAVR, cerebral embolic protection (Sentinel, Boston Scientific) did not decrease
    about 1 month ago
    healio.com

    Bioadaptor may flatten event curve after PCI, including in complex ...

    WASHINGTON — A bioadaptor implant adaptable to vessel physiology was linked to fewer target lesion failure events after 6 months compared with a drug-eluting stent, including in high-risk lesions, researchers reported. As Healio previously reported, in the main results of the INFINITY-SWEDEHEART trial of patients with CAD requiring PCI, the implant (DynamX bioadaptor scaffold, Elixir
    about 2 months ago